TRPV1 and diabetes mellitus: HUCMSCs ameliorate diabetic neuropathic pain primarily through activation of the TRPV1-[Ca2+]i-AMPK signaling pathway in SCs, which may provide a new molecular target for enhancing the clinical therapeutic effect of HUCMSCs on DPN.